drugset / Trial / NCT06164743

Phase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract Surgery

NCT06164743

Phase 2 Completed 91 enrolled VivaVision Biotech, Inc
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a multicenter, double-masked, randomized, vehicle-controlled, parallel-comparison study conducted at sites in the United States (US) in subjects undergoing routine unilateral cataract extraction and lens replacement (CELR) surgery via phacoemulsification

Timeline

Start
2024-01-11
Primary completion
2024-05-15
Completion
2024-05-15

Drugs

EvaluationDrugModalityDoseRoute
Subject VVN461 Unknown 0.5 % Topical
Subject VVN461 Unknown 1 % Topical

Indications

No indication recorded.